A detailed history of Sit Investment Associates Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sit Investment Associates Inc holds 59,900 shares of NTLA stock, worth $731,978. This represents 0.03% of its overall portfolio holdings.

Number of Shares
59,900
Previous 59,900 -0.0%
Holding current value
$731,978
Previous $1.34 Million 8.2%
% of portfolio
0.03%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $447,447 - $608,367
22,350 Added 59.52%
59,900 $1.34 Million
Q1 2024

May 14, 2024

BUY
$23.82 - $32.8 $73,842 - $101,679
3,100 Added 9.0%
37,550 $1.03 Million
Q2 2023

Aug 10, 2023

BUY
$34.58 - $46.03 $338,019 - $449,943
9,775 Added 39.61%
34,450 $1.41 Million
Q1 2023

May 11, 2023

BUY
$33.3 - $44.82 $821,677 - $1.11 Million
24,675 New
24,675 $920,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $929M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Sit Investment Associates Inc Portfolio

Follow Sit Investment Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sit Investment Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sit Investment Associates Inc with notifications on news.